Founded in 1994, Exelixis, Inc. is a biotechnology company dedicated to improving the lives of cancer patients. The company's mission is to help patients recover stronger and live longer by developing and commercializing innovative and effective oncology therapies. Its primary commercial product is CABOMETYX® (cabozantinib), which is approved for treating several types of cancer, including advanced renal cell carcinoma. Exelixis focuses on a full range of activities, from drug discovery and research to clinical development and global commercialization, often through strategic partnerships to expand the reach of its medicines.

Founded in

Greece